Corcept Therapeutics Incorporated (LON:0I3Q)
68.40
-3.38 (-4.71%)
At close: Jul 7, 2025
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $157.21M USD in the quarter ending March 31, 2025, with 7.09% growth. This brings the company's revenue in the last twelve months to $685.45M, up 30.93% year-over-year. In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth.
Revenue (ttm)
$685.45M
Revenue Growth
+30.93%
P/S Ratio
10.61
Revenue / Employee
$1.37M
Employees
500
Market Cap
5.63B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Indivior | 905.57M |
Corcept Therapeutics News
- 11 days ago - Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators - Seeking Alpha
- 17 days ago - Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care - Benzinga
- 17 days ago - Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care - Business Wire
- 21 days ago - Insider Decision: Gary Charles Robb Offloads $225K Worth Of Corcept Therapeutics Stock - Benzinga
- 27 days ago - Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring - Seeking Alpha
- 27 days ago - Major Update: LEONARD BAKER JR At Corcept Therapeutics Exercises Options, Realizing $0 - Benzinga
- 4 weeks ago - 20 stocks you should avoid — no matter how well the market does - Market Watch
- 5 weeks ago - Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - Business Wire